Please Wait...

Joyce Suhy

Translation skills

Main profile

Joyce Suhy, Ph.D.
Vice President & Head of Neuroscience and Cardiovascular Services

Dr. Joyce Suhy is responsible for the Neuroscience and Cardiovascular Services at Bioclinica. Dr. Suhy leads the design and scientific oversight of the imaging endpoints for these clinical trials and provides training to staff involved in these studies. Dr. Suhy has authored numerous journal articles and book chapters in imaging of the brain since 1992.  Prior to joining Bioclinica, Dr. Suhy worked at Synarc, where she was the VP of Neuroscience, and at SurroMed, Inc. where she was a Clinical Research Specialist responsible for the development, design, and evaluation of a standardized protocol for multiple sclerosis. Dr. Suhy received her Bachelor’s degree in Chemistry from Northwestern University and her PhD in Biochemistry from Loyola University Chicago. She completed her Post-Doctoral Research Fellowship in the Department of Radiology at the University of California at San Francisco where her work focused on utilizing MR spectroscopy and imaging to quantify metabolites within the human brain as a method to diagnose and predict the onset of neurodegenerative diseases such as epilepsy, multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis. Dr. Suhy is a recipient of many honors and grant awards including a Co-Principal Investigator NIH RO1 Grant, a Principal Investigator NIH National Research Service Award and a Principal Investigator National MS Society Fellowship. She has authored numerous journal articles and book chapters in the neuroscience therapeutic area and has participated on several expert panels to advance the use of imaging in clinical trials.

 

Authored Publications

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.

Carlson C, Siemers E, Hake A, Case M, Hayduk R, Suhy J, Oh J, Barakos J.

Alzheimers Dement (Amst). 2016 Mar 2;2:75-85. doi: 10.1016/j.dadm.2016.02.004. eCollection 2016.

 

Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort.

Tosun D, Chen YF, Yu P, Sundell KL, Suhy J, Siemers E, Schwarz AJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2016 Sep;12(9):977-986. doi: 10.1016/j.jalz.2016.03.009. Epub 2016 Apr 22

 

Deformation-based atrophy computation by surface propagation and its application to Alzheimer's disease.

Pai A, Sporring J, Darkner S, Dam EB, Lillholm M, Jørgensen D, Oh J, Chen G, Suhy J, Sørensen L, Nielsen M.

J Med Imaging (Bellingham). 2016 Jan;3(1):014005. doi: 10.1117/1.JMI.3.1.014005. Epub 2016 Mar 16

 

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.

Sevigny J, Suhy J, Chiao P, Chen T, Klein G, Purcell D, Oh J, Verma A, Sampat M, Barakos J.

Alzheimer Dis Assoc Disord. 2016 Jan-Mar;30(1):1-7. doi: 10.1097/WAD.0000000000000144.

 

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Sep;11(9):1050-68. doi: 10.1016/j.jalz.2014.09.004. Epub 2014 Nov 24. Review.

 

Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease.

Hill DL, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L, Boccardi M, Brewer J, Brumfield M, Cantillon M, Cole PE, Fox N, Frisoni GB, Jack C, Kelleher T, Luo F, Novak G, Maguire P, Meibach R, Patterson P, Bain L, Sampaio C, Raunig D, Soares H, Suhy J, Wang H, Wolz R, Stephenson D.

Alzheimers Dement. 2014 Jul;10(4):421-9.e3. doi: 10.1016/j.jalz.2013.07.003.

 

Chemoenzymatic resolution of rac-malathion.

Hitt DM, Belabassi Y, Suhy J, Berkman CE, Thompson CM.

Tetrahedron Asymmetry. 2014 Apr 15;25(6-7):529-533.

 

The future of blood-based biomarkers for Alzheimer's disease.

Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW; Blood-Based Biomarker Interest Group.

Alzheimers Dement. 2014 Jan;10(1):115-31. doi: 10.1016/j.jalz.2013.01.013. Epub 2013 Jul 11. Review.

 

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.

Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P; EU/US/CTAD Task Force Members.

Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.


An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function.

Henriksen K, Wang Y, Sørensen MG, Barascuk N, Suhy J, Pedersen JT, Duffin KL, Dean RA, Pajak M, Christiansen C, Zheng Q, Karsdal MA.

PLoS One. 2013 May 22;8(5):e64990. doi: 10.1371/journal.pone.0064990. Print 2013.

 

Standardization of analysis sets for reporting results from ADNI MRI data.

Wyman BT, Harvey DJ, Crawford K, Bernstein MA, Carmichael O, Cole PE, Crane PK, DeCarli C, Fox NC, Gunter JL, Hill D, Killiany RJ, Pachai C, Schwarz AJ, Schuff N, Senjem ML, Suhy J, Thompson PM, Weiner M, Jack CR Jr; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 May;9(3):332-7. doi: 10.1016/j.jalz.2012.06.004. Epub 2012 Oct 27.


Task force on Alzheimer's disease trial methodology: recruitment and retention, data management and analysis. The use of imaging in recruitment: maintenance and methodological issues in Alzheimer's trials.

Suhy J.

J Nutr Health Aging. 2012 Apr;16(4):349-51.

 

Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.

Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, Mintun M, Morris J, Petersen R, Thomas RG, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio C, Aisen P; Task Force Participants.

J Nutr Health Aging. 2012 Apr;16(4):339-45.

 

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).

Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC, Sampalis J.

Arch Med Sci. 2011 Feb;7(1):102-11. doi: 10.5114/aoms.2011.20612. Epub 2011 Mar 8.

 

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease.

Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL.

Alzheimers Dement. 2011 Jul;7(4):474-485.e4. doi: 10.1016/j.jalz.2011.04.007.

 

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.

Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, Barakos J.

Alzheimers Dement. 2011 Jul;7(4):396-401. doi: 10.1016/j.jalz.2011.05.2353.

 

Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease.

Weiner MW, Sadowsky C, Saxton J, Hofbauer RK, Graham SM, Yu SY, Li S, Hsu HA, Suhy J, Fridman M, Perhach JL.

Alzheimers Dement. 2011 Jul;7(4):425-35. doi: 10.1016/j.jalz.2010.09.003. Epub 2011 Jun 8.

 

An MRI substudy of a donepezil clinical trial in mild cognitive impairment.

Schuff N, Suhy J, Goldman R, Xu Y, Sun Y, Truran-Sacrey D, Murthy A.

Neurobiol Aging. 2011 Dec;32(12):2318.e31-41. doi: 10.1016/j.neurobiolaging.2010.04.005. Epub 2010 Jun 11.

 

Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.

Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J.

J Nutr Health Aging. 2009 Jun;13(6):550-7. Erratum in: J Nutr Health Aging. 2010 Jan;14(1):80.

 

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience.

Saumier D, Aisen PS, Gauthier S, Vellas B, Ferris SH, Duong A, Suhy J, Oh J, Lau W, Garceau D, Haine D, Sampalis J.

J Nutr Health Aging. 2009 Apr;13(4):370-2

 

Neuroradiological findings in vascular dementia.

Guermazi A, Miaux Y, Rovira-Cañellas A, Suhy J, Pauls J, Lopez R, Posner H.

Neuroradiology. 2007 Jan;49(1):1-22. Epub 2006 Nov 18. Review

 

Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study.

Rule RR, Suhy J, Schuff N, Gelinas DF, Miller RG, Weiner MW.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5(3):141-9.

 

Imaging in antiangiogenesis trial: a clinical trials radiology perspective.

Kothari M, Guermazi A, White D, Suhy J, Reinhold C.

Br J Radiol. 2003;76 Spec No 1:S92-6. Review.

 

Biochemical and psychiatric predictors of Li(+) response and toxicity in Li(+)-treated bipolar patients.

Layden BT, Minadeo N, Suhy J, Abukhdeir AM, Metreger T, Foley K, Borge G, Crayton JW, Bryant FB, de Freitas DM.

Bipolar Disord. 2004 Feb;6(1):53-61.

 

Testing competing path models linking the biochemical variables in red blood cells from Li+-treated bipolar patients.

Williams N, Layden BT, Suhy J, Metreger T, Foley K, Abukhdeir AM, Borge G, Crayton J, Bryant FB, Mota de Freitas D.

Bipolar Disord. 2003 Oct;5(5):320-9.

 

Spectroscopic metabolic abnormalities in mTLE with and without MRI evidence for mesial temporal sclerosis using hippocampal short-TE MRSI.

Mueller SG, Laxer KD, Suhy J, Lopez RC, Flenniken DL, Weiner MW.

Epilepsia. 2003 Jul;44(7):977-80.

 

Reduced extrahippocampal NAA in mesial temporal lobe epilepsy.

Mueller SG, Suhy J, Laxer KD, Flenniken DL, Axelrad J, Capizzano AA, Weiner MW.

Epilepsia. 2002 Oct;43(10):1210-6.

 

1H MRSI predicts surgical outcome in MRI-negative temporal lobe epilepsy.

Suhy J, Laxer KD, Capizzano AA, Vermathen P, Matson GB, Barbaro NM, Weiner MW.

Neurology. 2002 Mar 12;58(5):821-3.

 

Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI.

Suhy J, Miller RG, Rule R, Schuff N, Licht J, Dronsky V, Gelinas D, Maudsley AA, Weiner MW.

Neurology. 2002 Mar 12;58(5):773-9.

 

1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Suhy J, Rooney WD, Goodkin DE, Capizzano AA, Soher BJ, Maudsley AA, Waubant E, Andersson PB, Weiner MW.

Mult Scler. 2000 Jun;6(3):148-55.

 

Below publications under maiden name Nikolakopoulos:

 

Competition between Li+ and Mg2+ in neuroblastoma SH-SY5Y cells: a fluorescence and 31P NMR study.

Amari L, Layden B, Nikolakopoulos J, Rong Q, Mota de Freitas D, Baltazar G, Castro MM, Geraldes CF.

Biophys J. 1999 Jun;76(6):2934-42

 

7Li nuclear magnetic resonance study for the determination of Li+ properties in neuroblastoma SH-SY5Y cells.

Nikolakopoulos J, Zachariah C, Mota de Freitas D, Stubbs EB Jr, Ramasamy R, Castro MC, Geraldes CF.

J Neurochem. 1998 Oct;71(4):1676-84.

 

Comparison of the use of gel threads and microcarrier beads in Li+ transport studies of human neuroblastoma SH-SY5Y cells. (1996) J. Nikolakopoulos, C. Zachariah, D. Mota de Freitas, C.F.G.C. Geraldes. Inorganica Chimica Acta, vol 251 p. 201-205

 

Authored Book Chapters

7Li NMR study of lithium ion transport in perfused human neuroblastoma cells (1996) C. Zachariah, J. Nikolakopoulos, D. Mota de Freitas, E.B. Stubbs Jr., M.M.C.A. Castro, C.F.G.C. Geraldes, M. Lima, C.R. Oliveira, R. Ramasamy. Lithium: Biochemical and Clinical Advances. V.Gallicchio, N.Birch (eds).Weidner Publishing Group, Chestire, CT. p.211-230.

 

7Li NMR study of lithium ion transport in perfused human neuroblastoma cells. (1996) M. Castro, J. Nikolakopoulos, C. Zachariah, D.M. Freitas, E.B. Stubbs Jr., C.F.G.C. Geraldes, R. Ramasamy. Metals in Biology and Medicine, vol 4. P. Collery, J. Corbella, J. Domingo, J. Etienne, J. Llobet, (eds). John Libbey Eurotext, Paris. p. 192-194.

 

Li+ transport properties in perfused neuronal cells by 7Li NMR spectroscopy. (1996) M. Castro, J. Nikolakopoulos, C. Zachariah, D.M. de Freitas, C.F.G.C. Geraldes, R. Ramasamy. Cytotoxic, Mutagenic and Carcinogenic Potential of Heavy Metals Related to Human Environment, N.D. Hadjiliadis (ed.). Kluwer Academic Publishers, Netherlands, p. 311-321.

Authored Publications

Henriksen K, Wang Y, Sørensen MG, Barascuk N, Suhy J, Pedersen JT, Duffin KL, Dean RA, Pajak M, Christiansen C, Zheng Q, Karsdal MA. An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function. PLoS One. 2013 May 22;8(5).

Hitt DM, Belabassi Y, Suhy J, Berkman CE, Thompson CM. Chemoenzymatic resolution of rac-malathion. Tetrahedron Asymmetry. 2014 Apr 15;25(6-7):529-533.

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W; Alzheimer's Disease Neuroimaging Initiative. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2014 Nov 24. P1-19.

Schuff N, Suhy J, Goldman R, Xu Y, Sun Y, Truran-Sacrey D, Murthy A. An MRI substudy of a donepezil clinical trial in mild cognitive impairment. Neurobiol Aging. 2011 Dec;32(12):2318.e31-41.

Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement. 2011 Jul;7(4):474-485.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

If study sites R asking 4 accuracy & speed in site payments & the clinical financial folks R demanding better budge… https://t.co/FR4QE2QEqx
bioclinica (7 hours ago)
See you at #DIA2018 ! Here's when & where to find @Bioclinica in our exhibit, at Innovation Theater (Site Payments!… https://t.co/z4hPha2Ppo
bioclinica (Yesterday)
Reminder: Today's webinar on Clinical Endpoint Adjudication kicks off at 1 PM Eastern. > https://t.co/1IU9TVFCFA
bioclinica (5 days ago)
In a new go-to-guide on conducting #Alzheimer's clinical trials, @bioclinica experts Joyce Suhy, Marieke Cajal, Luc… https://t.co/SaBFm3L9CL
bioclinica (6 days ago)
Clinical Endpoint Adjudication Webinar. Join us in a live online event this Friday, (6/15) Details & reg. > https://t.co/uBjlgSMnDS
bioclinica (6 days ago)
Clinical Endpoint Adjudication webinar this Friday! Interested in establishing a universal clinical vocabulary to i… https://t.co/uPD992tSaY
bioclinica (1 week ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen